Novavax, Inc. (NASDAQ:NVAX) – Analysts at Seaport Global Securities issued their FY2017 earnings estimates for shares of Novavax in a report issued on Friday. Seaport Global Securities analyst V. Bernardino expects that the biopharmaceutical company will post earnings per share of ($0.63) for the year. Seaport Global Securities currently has a “Neutral” rating on the stock.
Novavax (NASDAQ:NVAX) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.16). The firm had revenue of $6.70 million for the quarter, compared to analysts’ expectations of $6.15 million. Novavax had a negative return on equity of 787.38% and a negative net margin of 1,006.00%. The business’s quarterly revenue was up 168.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.29) EPS.
ILLEGAL ACTIVITY NOTICE: This article was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://ledgergazette.com/2017/10/10/fy2017-earnings-estimate-for-novavax-inc-issued-by-seaport-global-securities-nvax.html.
Several other research analysts have also commented on the company. Zacks Investment Research lowered Novavax from a “buy” rating to a “hold” rating in a research report on Saturday, August 19th. BidaskClub upgraded Novavax from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Ladenburg Thalmann Financial Services upgraded Novavax from a “neutral” rating to a “buy” rating and set a $1.60 price target for the company in a research report on Wednesday, August 9th. Chardan Capital reiterated a “neutral” rating and issued a $1.50 price target on shares of Novavax in a research report on Thursday, July 27th. Finally, Piper Jaffray Companies reiterated a “hold” rating and issued a $1.50 price target on shares of Novavax in a research report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, eight have given a hold rating and two have issued a buy rating to the company’s stock. Novavax currently has a consensus rating of “Hold” and a consensus price target of $3.05.
Shares of Novavax (NASDAQ NVAX) opened at 1.16 on Monday. The company’s market cap is $336.28 million. The firm has a 50-day moving average price of $1.12 and a 200 day moving average price of $1.06. Novavax has a 1-year low of $0.73 and a 1-year high of $1.93.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Raymond James Financial Services Advisors Inc. raised its stake in shares of Novavax by 49.8% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 89,697 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 29,800 shares in the last quarter. Profund Advisors LLC raised its stake in shares of Novavax by 0.4% during the second quarter. Profund Advisors LLC now owns 120,775 shares of the biopharmaceutical company’s stock valued at $139,000 after acquiring an additional 455 shares in the last quarter. Voya Investment Management LLC raised its stake in shares of Novavax by 18.6% during the second quarter. Voya Investment Management LLC now owns 138,270 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 21,639 shares in the last quarter. HighTower Advisors LLC raised its stake in shares of Novavax by 3.8% during the first quarter. HighTower Advisors LLC now owns 142,000 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 5,250 shares in the last quarter. Finally, American International Group Inc. raised its stake in shares of Novavax by 7.1% during the first quarter. American International Group Inc. now owns 166,252 shares of the biopharmaceutical company’s stock valued at $213,000 after acquiring an additional 10,965 shares in the last quarter. 45.17% of the stock is owned by institutional investors and hedge funds.
In other Novavax news, Director James F. Young sold 175,000 shares of the firm’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $1.06, for a total value of $185,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.00% of the stock is owned by company insiders.
Novavax Company Profile
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.